Welcome to the international HTA database

Showing [24040 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	National Institute for Health and Care Excellence (NICE)	Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 422
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Tonsil surgery: comparison of intracapsular dissections and extracapsular dissections and dentification of children at risk for hemorrhage]
2016	NIHR Health Technology Assessment programme	Orthotic management of instability of the knee related to neuromuscular and central nervous system disorders: systematic review, qualitative study, survey and costing analysis
2016	Health Quality Ontario (HQO)	Levonorgestrel-releasing intrauterine sSystem (52 mg) for idiopathic heavy menstrual bleeding: a health technology assessment
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Economic analysis of peripherally inserted central venous catheters (PICC), inserted by nursing staff, in cancer and hematological patients]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab - Addendum to Commission A15-32]
2016	National Institute for Health and Care Excellence (NICE)	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens. NICE technology appraisal guidance 423
2016	NIHR Health Technology Assessment programme	The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis
2016	NIHR Public Health Research (PHR) programme	Implications for public health research of models and theories of disability: a scoping study and evidence synthesis
2016	Health Quality Ontario (HQO)	Transcatheter aortic valve implantation for treatment of aortic valve stenosis: a health technology assessment
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Interventions to improve CPAP treatment adherence in patients with obstructive sleep apnea]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab - Addendum to Commission A15-33]
2016	National Institute for Health and Care Excellence (NICE)	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer. NICE technology appraisal guidance 424
2016	NIHR Health Technology Assessment programme	A randomised controlled trial to measure the effects and costs of a dental caries prevention regime for young children attending primary care dental services: the Northern Ireland Caries Prevention In Practice (NIC-PIP) trial
2016	NIHR Health Technology Assessment programme	Social Stories to alleviate challenging behaviour and social difficulties exhibited by children with autism spectrum disorder in mainstream schools: design of a manualised training toolkit and feasibility study for a cluster randomised controlled trial with nested qualitative and cost-effectiveness components
2016	NIHR Health Technology Assessment programme	Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation
2016	NIHR Health Services and Delivery Research programme	Do-not-attempt-cardiopulmonary-resuscitation decisions: an evidence synthesis
2016	NIHR Health Services and Delivery Research programme	The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Prenatal screening for Down syndrome through fetal DNA sequencing from maternal blood]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tiotropium/olodaterol - Addendum to Commission A15-31]
2016	National Institute for Health and Care Excellence (NICE)	Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. NICE technology appraisal guidance 425
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Everolimus (Afinitor) for diffuse large B-cell lymphoma – maintenance therapy
2016	NIHR Health Services and Delivery Research programme	Determining the optimal model for role substitution in NHS dental services in the UK: a mixed-methods study
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation
2016	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Acute neck and back pain: preventive interventions – Effects of physical training, manual treatment and cognitive behavioral interventions]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pertuzumab - Addendum to Commission A15-34]
2016	National Institute for Health and Care Excellence (NICE)	Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. NICE technology appraisal guidance 426
2016	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Dabrafenib (Tafinlar) and trametinib (Mekinist) combination therapy for advanced BRAF mutated non-small cell lung cancer
2016	Adelaide Health Technology Assessment (AHTA)	Microwave tissue ablation for primary and secondary liver cancer
2016	Health Quality Ontario (HQO)	Levonorgestrel-releasing intrauterine system (52 mg) for idiopathic heavy menstrual bleeding: OHTAC Recommendation
2016	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prenatal diagnosis through Next Generation Sequencing (NGS)]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Isavuconazole - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2016	NIHR Horizon Scanning Centre (NIHR HSC)	ADI-PEG 20 for hepatocellular carcinoma – second line
2016	Health Quality Ontario (HQO)	Transcatheter aortic valve implantation for treatment of aortic valve stenosis: OHTAC recommendation
2016	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prenatal diagnosis through Chromosomal Microarray Analysis (CMA)]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Searches in trial registries for studies on newly approved drugs]
2016	NIHR Health Technology Assessment programme	An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft
2016	NIHR Public Health Research (PHR) programme	IMPRoving Outcomes for children exposed to domestic ViolencE (IMPROVE): an evidence synthesis
2016	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Drug treatment of children with respiratory tract infections - a scoping review]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alirocumab - Benefit assessment according to §35a Social Code Book V]
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Furosemide sc2Wear micro-pump patch for oedema in heart failure
2016	NIHR Health Services and Delivery Research programme	Getting the most out of knowledge and innovation transfer agents in health care: a qualitative study
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploratory examination of the need for revision of the DMP "coronary heart disease"]
2016	NIHR Health Technology Assessment programme	A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC)
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pertuzumab (Perjeta) with chemotherapy and trastuzumab for HER2-positive early breast cancer – adjuvant therapy
2016	NIHR Health Services and Delivery Research programme	Location of care for people with serious mental illness (LOCAPE): implications for service use and costs using a mixed-methods approach
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dabrafenib/trametinib - Addendum to Commissions A15-39 and A15-40]
2016	National Evidence-based Healthcare Collaborating Agency (NECA)	[Study of horizon scanning and potential health impact assessment of emerging health technology and development of operation system of H-SIGHT]
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Remestemcel-L for graft vs host disease in paediatric patients – second line
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Models for providing care and services to patients who have concurrent mental health and substance use disorders]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pomalidomide - Addendum to Commission A15-42]
2015	Institute for Clinical Evaluative Sciences (ICES)	The mental health of children and youth in Ontario: a baseline scorecard
2015	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Once more a test title
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[The status and dissemination plan of clinical practice guidelines in Korea]
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) for PD-L1 strong-positive metastatic non-small cell lung cancer – first line
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis
2015	Basque Office for Health Technology Assessment (OSTEBA)	[Evaluation of the use of the new tools 2.0 and the social web in the diffusion and dissemination of the products of the agencies and units of Health Technology Assessment]
2015	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Hysteroscopy for abnormal uterine bleeding: review of clinical evidence and guidelines
2015	Institute for Clinical Evaluative Sciences (ICES)	Atlas of childhood cancer in Ontario 1985-2004
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[Analysis for healthcare safety management system]
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Glycerol phenylbutyrate (Ravicti) for urea cycle disorders (hyperammonaemia)
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	23g and 25g vitrectomy for eye conditions
2015	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	And another test title
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[Clinical safety and effectiveness of robotic surgery (2)]
2015	NIHR Horizon Scanning Centre (NIHR HSC)	GSK2696273 for severe combined immunodeficiency due to adenosine deaminase deficiency
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	Actigraphy in sleep disorder assessment
2015	Basque Office for Health Technology Assessment (OSTEBA)	[Ophthalmic implants in glaucoma surgery. Safety and effectiveness analysis]
2015	Center for Drug Evaluation (CDE)	[Transcatheter aortic valve implantation (TAVI) HTA report]
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[Pilot study for understanding the present situation of decorative tattoos]
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Holkira (ombitasvir/paritaprevir/ ritonavir with dasabuvir) and Harvoni (ledipasvir/sofosbuvir) for chronic hepatitis C: a review of the clinical evidence
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Lopixibat for progressive familial intrahepatic cholestasis in paediatric patients
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	Gene panels in autistic spectrum disorders
2015	Basque Office for Health Technology Assessment (OSTEBA)	[Cost effective analysis of negative pressure wound therapy for the treatment of venous ulcers in legs]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ocular biometry of the anterior chamber depth using IOL Master® and Pentacam®]
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[Research for extending the scope of health technology assessment (HTA): focusing on tobacco control]
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Vitamin D testing in the general population: a review of the clinical and cost-effectiveness and guidelines
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Masitinib for Crohn's disease, in patients intolerant or with an unsatisfactory response to immunosuppressive drugs and/or TNF-inhibitors
2015	Basque Office for Health Technology Assessment (OSTEBA)	[E-health systems to support cancer patients: proposal for the design of future assessment studies]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Exantia® tissue bulking agent for the treatment of fecal incontinence]
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[NECA Round Table Conference for social consensus]
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Masitinib for primary and relapse-free secondary progressive multiple sclerosis – first line
2015	Basque Office for Health Technology Assessment (OSTEBA)	[Arthroscopy with joint washout in the treatment of knee arthrosis]
2015	Finnish Office for Health Care Technology Assessment (Finohta)	[Role of fractional exhaled nitric oxide (FeNO) measurement in the management of asthma with corticosteroids]
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Biologic agents for the treatment of psoriasis]
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[Priority setting for health technology assessment(HTA) research in Korea]
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Telehealth services for the treatment of psychiatric issues: clinical effectiveness, safety, and guidelines
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Masitinib for rheumatoid arthritis – second and subsequent line
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Ranibizumab, bevacizumab and aflibercept for age-related macular degeneration]
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[A construction of support scheme for health technology evidence-generation in Korea]
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Sirukumab for rheumatoid arthritis
2015	NIHR Health Technology Assessment programme	A feasibility randomised controlled trial of a motivational interviewing-based intervention for weight loss maintenance in adults
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Haploidentical bone marrow transplantation in patients with blood cancers]
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[The economic analysis of robotic surgery for prostate cancer]
2015	Canadian Agency for Drugs and Technologies in Health (CADTH)	Electroconvulsive therapy performed outside of surgical suites: a review of the clinical effectiveness, safety, and guidelines
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Tadalafil (Cialis) for Duchenne muscular dystrophy
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	[Subcutaneous histamine in migraine prevention]
2015	Technology Assessment at SickKids (TASK)	Thiopurine S-methyltransferase testing for averting drug toxicity in patients receiving thiopurines: A systematic review and quality appraisal